- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.12.25 | Pfizer's $2bn+ obesity bet, and other weight-loss news | ||
| 10.12.25 | Hims & Hers launches weight-loss business in UK | ||
| 10.12.25 | Are RSV shots next in line for restrictions in the US? | ||
| 10.12.25 | FDA clears first gene therapy for rare genetic disease WAS | ||
| 10.12.25 | UK confirms lower clawback rate for NHS medicines | ||
| 10.12.25 | Antibiotic is first approval in FDA national priority scheme | ||
| 09.12.25 | FDA set to raise bar for clinical trials of CAR-T therapies | ||
| 09.12.25 | Lab-in-a-loop specialist Relation attracts Novartis alliance | ||
| 09.12.25 | FDA backs first AI tool for use in trials, targeting MASH | ||
| 09.12.25 | ASH: Jaypirca matches Imbruvica in first-line CLL trial | ||
| 09.12.25 | ASH: FDA okays Gamida aplastic anaemia therapy as data drops | ||
| 08.12.25 | ASH: Gilead preps filing for anito-cel on iMMagine-1 data | ||
| 08.12.25 | ASH: Regeneron makes frontline case for Lynozyfic in myeloma | ||
| 08.12.25 | FDA reveals real-world pilot for digital health tools | ||
| 05.12.25 | CDC panel votes to scrap hepatitis B birth dose advice | ||
| 05.12.25 | Praxis soars on rare childhood epilepsy trial data | ||
| 05.12.25 | Protego's $130m for amyloidosis drug, and other financings | ||
| 05.12.25 | BMS's Breyanzi is first CAR-T for marginal zone lymphoma | ||
| 05.12.25 | Setback for MSD as German court blocks Keytruda SC launch | ||
| 05.12.25 | NHS use of digital cardiac rehab tools endorsed | ||
| 04.12.25 | NHS staff 'feel unprepared for digital transformation' | ||
| 04.12.25 | Lilly gets approval for earlier use of Jaypirca in CLL | ||
| 04.12.25 | FDA could hike user fees for ex-US drug programmes | ||
| 04.12.25 | Bayer takes Alport syndrome drug into phase 2 | ||
| 04.12.25 | Tracy Beth Hoeg will be fifth CDER head this year |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .